Evidence map›Paper›PMID 30865617›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Both Peripheral Blood and Urinary miR-195-5p, miR-192-3p, miR-328-5p and Their Target Genes PPM1A, RAB1A and BRSK1 May Be Potential Biomarkers for Membranous Nephropathy.

Guangyu Zhou, Xiaofei Zhang, Wanning Wang, Wenlong Zhang, Huaying Wang, Guangda Xin

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Novel Biomarkers in Membranous Nephropathy.Frontiers in immunology · 2022
    Review
  11. Review
  12. Article
  13. Article
  14. MicroRNAs as Biomarkers for Nephrotic Syndrome.International journal of molecular sciences · 2020
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Guangyu ZhouDepartment of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China (mainland).
Xiaofei ZhangDepartment of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China (mainland).
Wanning WangDepartment of Nephrology, The First Hospital of Jilin University, Changchun, Jilin, China (mainland).
Wenlong ZhangDepartment of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China (mainland).
Huaying WangDepartment of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China (mainland).
Guangda XinDepartment of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China (mainland).
Union Hospital · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND To identify noninvasive diagnostic biomarkers for membranous nephropathy (MN). MATERIAL AND METHODS The mRNA microarray datasets GSE73953 using peripheral blood mononuclear cells (PBMCs) of 8 membranous nephropathy patients and 2 control patients; and microRNAs (miRNA) microarray dataset GSE64306 using urine sediments of 4 membranous nephropathy patients and 6 control patients were downloaded from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) were respectively identified from PBMCs and urine sediments of membranous nephropathy patients, followed with functional enrichment analysis, protein-protein interaction (PPI) analysis, and miRNA-target gene analysis. Finally, the DEGs and the target genes of DEMs were overlapped to obtain crucial miRNA-mRNA interaction pairs for membranous nephropathy. RESULTS A total of 1246 DEGs were identified from PBMCs samples, among them upregulated CCL5 was found to be involved in the chemokine signaling pathway, and BAX was found to be apoptosis related; while downregulated PPM1A and CDK1 were associated with the MAPK signaling pathway and the p53 signaling pathway, respectively. The hub role of CDK1 (degree=18) and CCL5 (degree=12) were confirmed after protein-protein interaction network analysis in which CKD1 could interact with RAB1A. A total of 28 DEMs were identified in urine sediments. The 276 target genes of DEMs were involved in cell cycle arrest (PPM1A) and intracellular signal transduction (BRSK1). Thirteen genes were shared between the DEGs in PMBCs and the target genes of DEMs in urine sediments, but only hsa-miR-192-3p-RAB1A, hsa-miR-195-5p-PPM1A, and hsa-miR-328-5p-BRSK1 were negatively related in their expression level. CONCLUSIONS Both peripheral blood and urinary miR-195-5p, miR-192-3p, miR-328-5p, and their target genes PPM1A, RAB1A, and BRSK1 may be potential biomarkers for membranous nephropathy by participating in inflammation and apoptosis.

Indexed as

BiomarkersComputational BiologyFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksGlomerulonephritis, MembranousHumansIntracellular Signaling Peptides and ProteinsMaleMicroRNAsProtein Interaction MapsProtein Phosphatase 2CProtein Serine-Threonine Kinasesrab1 GTP-Binding ProteinsSignal TransductionBiomarkersBRSK1 protein, humanIntracellular Signaling Peptides and ProteinsMicroRNAsMIRN192 microRNA, humanMIRN195 microRNA, humanMIRN328 microRNA, humanPPM1A protein, humanProtein Phosphatase 2CProtein Serine-Threonine Kinasesrab1 GTP-Binding Proteins

Identifiers

PMID30865617
PMCPMC6427931
OpenAlexW2921565525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.